A patent lawsuit involving a Pfizer brand and AstraZeneca is advancing, as a Delaware federal judge stated there are numerous “genuine factual disputes” preventing its premature conclusion. The Pfizer brand alleges they developed a cancer treatment drug that has been infringed upon by a drug from AstraZeneca, which in turn has generated billions in sales.
This matter of potential patent infringement, which is now heading to the jury, carries significant implications in the industry. Some analysts consider it crucial for AstraZeneca, a premier global bio-pharmaceutical company, and a prolific contributor in the development and manufacturing of prescription medicines.
For Pfizer, one of the world’s largest multinational pharmaceutical corporations, it’s an aggressive move to establish a claim on a successful cancer treatment drug. The implications of the lawsuit transcend these individual companies, potentially affecting drug developers and pharmaceutical corporations worldwide.
More details about the lawsuit can be found in the original report on Law360.